Mapping Pre-Cancer to Predict Oesophageal Cancer - Stanford Radiology CEDSS 2022

Mapping Pre-Cancer to Predict Oesophageal Cancer - Stanford Radiology CEDSS 2022

Stanford Radiology via YouTube Direct link

Summary

36 of 37

36 of 37

Summary

Class Central Classrooms beta

YouTube videos curated by Class Central.

Classroom Contents

Mapping Pre-Cancer to Predict Oesophageal Cancer - Stanford Radiology CEDSS 2022

Automatically move to the next video in the Classroom when playback concludes

  1. 1 Intro
  2. 2 TODAY'S CEDSS
  3. 3 Introducing oesophageal cancer adenocarcino increasing incidence and poor outcomes
  4. 4 Early detection in oesophageal cancer
  5. 5 Link between mutational processes in ageing and cancer - focus on pre-cancer
  6. 6 Predicting progression in Barrett's: Molecular drivers from benign to malignant
  7. 7 Treatments for oesophageal cancer
  8. 8 Curative therapy for dysplasia and early car
  9. 9 Is Barrett's always the precursor lesion?
  10. 10 Molecular phenotyping suggests gastric origin and malignant transition via Barrett's
  11. 11 Identifying at risk group for oesophagea adenocarcinoma
  12. 12 Risk factors and yield of screening
  13. 13 Device and Assay considerations
  14. 14 Pan-cancer cell free DNA tests
  15. 15 Breath biopsy and volatile analysis
  16. 16 Non-endoscopic device + liquid methylation a
  17. 17 Sample processing for Cytosponge
  18. 18 TFF3 a Barrett's (intestinal metaplasia) biomarker
  19. 19 Manual pathology review aided by TFF3 bion
  20. 20 Machine learning applied to Cytosponge sa
  21. 21 Correlation with TFF3 count and segment le
  22. 22 Clinical trials for Cytosponge screenir
  23. 23 Primary Endpoint Results from BEST3 trial
  24. 24 Clinical evidence base for Cytosponge-TFF3
  25. 25 Monitoring Barrett's patients for dysplasia: Clinical standard surveillance protocol
  26. 26 Relationship p53 and Barrett's dysplasia
  27. 27 Timing of events in Barrett's progression
  28. 28 P53 immunohistochemistry as adjunct to dysplasia diagnosis
  29. 29 Identifying Cytosponge biomarkers for dysp
  30. 30 Decision Tree for Cytosponge Surveilla
  31. 31 Dysplasia yield across risk groups retrospe
  32. 32 Prospective surveillance case-studies
  33. 33 Biomarkers beyond p53 and atypia: DNA copy number and progression status
  34. 34 Can altered DNA copy number (aneuploidy) add V
  35. 35 Potential to add copy number for Barrett's surveillance using Cytosponge
  36. 36 Summary
  37. 37 Funding Acknowledgments

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.